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The heterotrimeric Sec61 complex is a major site for the biogenesis of transmembrane
proteins (TMPs), accepting nascent TMP precursors that are targeted to the endoplasmic
reticulum (ER) by the signal recognition particle (SRP). Unlike most single-spanning mem-
brane proteins, the integration of type III TMPs is completely resistant to small molecule
inhibitors of the Sec61 translocon. Using siRNA-mediated depletion of specific ER compo-
nents, in combination with the potent Sec61 inhibitor ipomoeassin F (Ipom-F), we show that
type III TMPs utilise a distinct pathway for membrane integration at the ER. Hence, following
SRP-mediated delivery to the ER, type III TMPs can uniquely access the membrane insertase
activity of the ER membrane complex (EMC) via a mechanism that is facilitated by the Sec61
translocon. This alternative EMC-mediated insertion pathway allows type III TMPs to bypass
the Ipom-F-mediated blockade of membrane integration that is seen with obligate Sec61
clients.
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1 and mycolactone2,3 are natural pro-
ducts that inhibit the Sec61-mediated translocation of newly
synthesised polypeptides into and across the endoplasmic reti-
culum (ER) membrane. Both compounds are substrate selective;
effectively blocking the translocation of secretory proteins and the
ER integration of type I and type II transmembrane proteins
(TMPs) (Fig. 1a), but not affecting two type III TMPs (glycophorin
C; GypC and synaptotagmin 1; Syt1) studied to date1–3. Whilst this
behaviour suggests that type III TMPs may not follow a typical
pathway for ER integration1, earlier reconstitution studies suggested
that GypC could be membrane inserted via the Sec61 complex4.
Notably, the membrane insertion of tail-anchor (TA) proteins
(Fig. 1a) at the ER is also unaffected by Ipom-F and mycolactone,
consistent with substantial evidence that they can exploit one
or more Sec61-independent pathways5,6. Given the effectiveness of
the in vitro blockade of other Sec61-dependent clients observed
with Ipom-F and mycolactone1–3, we therefore considered the
possibility that, like TA proteins, type III TMPs may also be able to
insert into the ER membrane via one or more Sec61-independent,
pathway(s).
The ER membrane complex (EMC) is evolutionarily conserved
and its disruption has wide-ranging and pleiotropic effects on
membrane protein biogenesis7–15. Furthermore, the EMC has
recently been shown to act as an ER membrane insertase14,16,17
that is alone capable of mediating the post-translational insertion
of certain TA proteins18 and the co-translational insertion of the
first transmembrane domain of a multi-pass integral membrane
protein14,19. In the latter case when the first transmembrane
domain is studied in isolation it orients with its N-terminus on
the exoplasmic side of the membrane (Nexo), and on that basis it
might be viewed as a synthetic type III TMP (Fig. 1). However, in
the case of such multi-pass proteins, the insertion of subsequent
transmembrane domains is dependent on the Sec61 complex19.
Hence, it appears that the EMC and Sec61 complex act together
to provide a co-ordinated site for the membrane integration of a
subset of multi-pass TMPs at the ER14,17,19–21.
Given that ER-targeting and preliminary engagement of
ribosome-nascent chain complexes with the Sec61 translocon are
maintained in the presence of mycolactone22, and that type III
transmembrane domains have been shown to be in close proxi-
mity to the Sec61 complex during their membrane insertion23, a
‘sliding’ model24 has been proposed to explain the co-ordinated
actions of the Sec61 complex and the EMC. In this scenario,
following ribosome-nascent chain docking to the Sec61 complex,
the first transmembrane domain of some multi-pass TMPs may
insert headfirst (Nexo) into the ER membrane by using the EMC at
a location that is close to, but distinct from, the Sec61 lateral gate
that normally mediates transmembrane domain insertion14,19,24.
In the absence of the EMC, it is proposed that a small proportion
of such headfirst transmembrane domains, particularly those with
a more hydrophobic character, may be able to access the Sec61
lateral gate directly, although this interaction may result in an
inverted topology19,24.
Here, we explore the role of the Sec61 complex and the EMC
during membrane insertion by using a small panel of naturally
occurring single-pass type III TMPs, comprising one viral and
four mammalian proteins. We find that all five of our model type
III TMPs are efficiently inserted into ER-derived microsomes
even in the presence of Ipom-F1. Using semi-permeabilised (SP)
mammalian cells depleted of Sec61, EMC and/or signal recogni-
tion particle-(SRP) receptor subunits as an alternative source of
ER membranes25,26, we then probed their respective contribu-
tions to type III TMP biogenesis. Our data suggest that the ER
insertion of type III TMPs typically requires the combined actions
of both the Sec61 complex and the EMC, which act downstream
of an SRP-dependent delivery step.
Results
Type III TMPs are resistant to Ipom-F. To explore the biogenesis
of type III TMPs (Fig. 1a), we first used a well-established in vitro
system supplemented with ER-derived canine pancreatic micro-
somes (Fig. 1b) and exploited the Sec61 translocation inhibitor
Ipom-F (Fig. 1c)1. Using ER lumenal N-glycosylation as a reporter
for authentic membrane translocation1,2, we analysed the mem-
brane integration of a small, yet biochemically diverse, panel of
model type III TMPs in the presence and absence of Ipom-F. These
model type III TMPs are: human immunodeficiency virus protein
Vpu (HIV-Vpu), small cell adhesion glycoprotein (SMAGP), gly-
cophorin C (GypC), tumour necrosis factor receptor superfamily
member 17 (BCMA) and synaptotagmin 1 (Syt1), in most cases
modified to include N-glycosylation sites (see Fig. 1d and accom-
panying legend).
Following the resolution of radiolabelled products by SDS-
PAGE, we found that all five-model type III TMPs displayed
apparently normal levels of N-glycosylation in the presence of 1
µM Ipom-F (Fig. 1d, lane 1 versus lane 3 in each panel). Likewise,
the integration of two C-terminally tagged TA proteins was
unaffected by Ipom-F (Supplementary Fig. 1a), consistent with
their Sec61-independent biogenesis5. In contrast, 1 µM Ipom-F
substantially inhibits the ER translocation of secretory proteins
and the integration of type I and type II TMPs (Supplementary
Fig. 1b–d)1. Hence, Ipom-F consistently inhibits Sec61-mediated
translocation in a substrate selective manner that emulates the
actions of mycolactone1,2,27 and suggests that the integration of
type III TMPs is mechanistically distinct from other classes of
single-pass membrane proteins.
We next prepared SP cultured cells of human origin25,28 and
compared the effects of Ipom-F to those in canine pancreatic
microsomes. Excluding qualitative changes in the efficiency of
substrate N-glycosylation, the effects of Ipom-F were directly
comparable between microsomes and SP cells across the range of
substrates analysed (Supplementary Fig. 1E). Hence, type I and type
II TMPs were Ipom-F sensitive whilst a type III TMP was not. We
conclude the effects of Ipom-F on Sec61-mediated protein
translocation (Fig. 1 and Supplementary Fig. 1)1 is unaffected by
the source of ER-derived membrane29,30.
The effects of Sec61α and EMC5 knock-down on membrane
insertion are substrate selective. We next probed the roles of the
Sec61 complex and the EMC (Fig. 2a) in the membrane integration
of type III TMPs using SP cells transiently depleted of each complex.
Using well-characterised siRNAs, we targeted the central component
of the Sec61 complex31,32, Sec61α (Fig. 2b, c, lane 2)26, and two
subunits of the EMC, the cytosolic EMC2 (Fig. 2b, c, lane 3)33 and
the membrane-embedded EMC5 (Fig. 2b, c, lane 4)18, for knock-
down and determined the effects on protein levels (Fig. 2c) using
quantitative immunoblotting (Fig. 2d). Multimeric human EMC has
seven membrane-embedded and two cytosolic subunits (Supple-
mentary Fig. 2a) and siRNA-mediated knock-downs of EMC2 and
EMC5 destabilise the wider EMC10–14,18–20. Hence, we also immu-
noblotted for the EMC6 subunit, together with the OST48 subunit of
the oligosaccharyl-transferase (OST) complex, which served as an ER
localised control34, in order to confirm the specificity of our target
knock-downs.
Each knock-down selectively reduces expression of the target
without wide-ranging effects on ER membrane protein stability
per se (Fig. 2c, d) and has little (Sec61α knock-down) or
no (EMC2 or EMC5 knock-down) impact on OST activity10,26,
as judged by levels of OST48, a type I TMP and presumed
Sec61 client (Fig. 2b–d). Furthermore, based on our analysis of
EMC6 levels, we conclude that knock-down of EMC2, and, to
an even greater extent, EMC5 is sufficient to destabilise
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the wider EMC (Fig. 2c)10,14,16. In contrast, a knock-down of
Sec61α has no detectable effect on the three EMC subunits
studied (Fig. 2c). We noted a lack of any obvious canine EMC5
homologue, and speculate that an apparent increase in EMC6
detected in dog pancreatic microsomes (versus sheep) may be
compensatory (Fig. 2c, lane 5 versus lane 6, Supplementary
Fig. 2b and c).
We then investigated the effects of individual Sec61α, EMC2 or
EMC5 knock-downs (71, 44 and 88% depletion respectively;
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N-glycan site: Asn25
TMD ΔGapp: -3.43 kcal/mol








































































































































TMD ΔGapp: -3.77 kcal/mol
TMD charged/polar AAs: 5
N-glycan sites: Asn11,42
TMD ΔGapp: -4.10 kcal/mol
TMD charged/polar AAs: 3
N-glycan site: Asn2, 15
TMD ΔGapp: -3.32 kcal/mol
TMD charged/polar AAs: 1
N-glycan site: Asn8
TMD ΔGapp: -2.67 kcal/mol
TMD charged/polar AAs: 3
Fig. 1 Type III TMPs are resistant to Ipom-F. a Schematics of type I, type II, type III and tail-anchored (TA) proteins showing their topologies in the ER
membrane. b Outline of the in vitro assay where either canine pancreatic microsomes or semi-permeabilised HeLa cells were used as sources of ER
membrane; following translation, membrane inserted radiolabelled precursor proteins are recovered by centrifugation and analysed by SDS-PAGE and
phosphorimaging. The N-glycosylation of lumenal domains, confirmed by treatment with endoglycosidase H (Endo H), indicates successful membrane
translocation/insertion. c The chemical structure of ipomoeassin F (Ipom-F), a potent and selective inhibitor of Sec61-mediated protein translocation1.
d Model type III TMPs used in this study were synthesised as outlined in (b) using canine pancreatic microsomes: (di) an N-terminally OPG2-tagged form
of the HIV protein Vpu (OPG2Vpu), (dii) small cell adhesion glycoprotein containing an artificial N-glycosylation site (SMAGP), (diii) glycophorin C
(GypC), (div) tumour necrosis factor receptor superfamily member 17 containing an artificial N-glycosylation site (BCMA) and (dv) synaptotagmin 1
(Syt1). Variably N-glycosylated (XGly) and non-glycosylated (0Gly) species are indicated, having been confirmed using Endo H (lane 2). Other symbols
are: AAs, amino acid residues; Cyt, cytosol; Lum, ER lumen; RRL, rabbit reticulocyte lysate; s.s., N-terminal signal sequence. Estimated hydrophobicity
values (4Gapp)42 of predicted transmembrane domains (TMDs) in kcal /mol were calculated using: http://dgpred.cbr.su.se/ (full protein scan option).
Charged amino acid residues, D, E, H, K, R; polar amino acid residues, N, Q, S, T, Y.
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membrane proteins using SP cells depleted of each subunit
(Fig. 3a)28,34,35. A knock-down of Sec61α resulted in a >60%
reduction in the membrane integration of the type II TMP
asialoglycoprotein receptor (ASGR1OPG2; Fig. 3b) and no
further inhibition of ASGR1OPG2 insertion was achieved by
adding Ipom-F (Fig. 3c, d), consistent with the previously
reported Sec61-dependency of ASGR119,36,37 and Sec61α as the
primary target of Ipom-F1. As anticipated, knock-down of EMC5
had no effect on ASGR1OPG2 insertion, which remained
sensitive to Ipom-F treatment (Fig. 3c, d). Unexpectedly,
however, the modest knock-down of EMC2 (~44%) enhanced
the membrane integration of ASGR1OPG2 by >90%, perhaps
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Fig. 2 siRNA-mediated knock-down of Sec61α, EMC2 and EMC5. a Schematics of the Sec61 complex and the EMC. The heterotrimeric Sec61 complex (α,
β, γ subunits) forms a protein-conducting aqueous channel through which polypeptides are translocated into and across the ER membrane. Its actions are
regulated via a plug domain and lateral gate31,32. The EMC is organised into a basket-shaped cytosolic domain (EMC2, EMC8/9), a transmembrane-
spanning region (EMC3, EMC5, EMC6) and an L-shaped lumenal region (EMC1, EMC4, EMC7, EMC10). The insertase site is formed by EMC3/EMC6 near
the cytosolic vestibule, whilst the hydrophobic cleft may have a role in client transmembrane domain capture11–14. b Outlines of targets for siRNA-mediated
knock-down: Sec61α, EMC2, EMC5, together with additional proteins EMC6 and OST48 (48 kDa subunit of the oligosaccharyl-transferase complex)
analysed by immunoblotting are shown. LMNB1, (Lamin-B1) was used as a loading control for the quantity of SP cells used in each experiment. TMD,
transmembrane domain; TMP, transmembrane protein. c The effects of transfecting HeLa cells with non-targeting (NT; lane 1), Sec61α-targeting (lane 2),
EMC2-targeting (lane 3) and EMC5-targeting (lane 4) siRNAs were determined after semi-permeabilisation by immunoblotting for Sec61α, EMC2, EMC5
and EMC6 subunits, OST48 and LMNB1. ER-derived microsomes (µsomes) of dog (lane 5) and sheep (lane 6) origin were immunoblotted for the same
components. d The efficiencies of siRNA-mediated knock-down (bold) were calculated as a proportion of the signal intensity obtained with the NT control
(set as 100%). Bar quantifications are given as means ± SEM for four separate siRNA treatments (n= 4, biologically independent experiments) with
statistical significance of siRNA-mediated knock-downs (two-way ANOVA, DF and F values shown in the figure) determined using Tukey’s multiple
comparisons test. Statistical significance is given as n.s., non-significant P > 0.1; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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In contrast, the membrane insertion of the TA protein cytochrome
b5 (Cytb5OPG2; Fig. 3b) was reduced by ~70% for the EMC5 knock-
down and ~50% for the less-efficient EMC2 depletion, whilst its
integration is not significantly impaired following knock-down of
Sec61α or by the addition of Ipom-F (Fig. 3c, d). These data further
support the view that Cytb5 can exploit multiple, often redundant,
pathways of ER membrane insertion5,18,38–41 and confirm the fidelity
and efficiency of N-glycosylation for each knock-down condition
even when key components of the N-glycosylation machinery, such
as OST4810,26, may be reduced following knock-down of Sec61α.
Taken together, these findings show that using a knock-down
approach we can distinguish at least two different routes for the
insertion of single-pass TMPs into the ER. The first, as
exemplified by ASGR1, is sensitive to Ipom-F1, utilises the
Sec61 translocon36 and is unaffected by depletion of EMC519
(Fig. 3e). The second, as illustrated by Cytb5, exhibits a strong
dependency on the EMC for membrane integration, but appears
unaffected by loss of Sec61 function.
Type III TMPs variably utilise the EMC as an ER membrane
insertase. Having incorporated an OPG2-tag into each of our
model type III proteins and confirmed their continued resistance
to Ipom-F (Supplementary Fig. 3, see also “Methods”), we pro-
ceeded to use SP cells to probe the potential role of the EMC
during the insertion of type III TMPs by comparing the effects of
EMC depletion with loss of Sec61α function through both siRNA-
mediated knock-down and Ipom-F inhibition (Fig. 4). Consistent
with their resistance to the inhibitory effects of Ipom-F, four of
the five type III TMPs studied were unaffected by the depletion of
Sec61α whether or not Ipom-F was also present (Fig. 4b, c, see:
OPG2Vpu, SMAGPOPG2, BCMAOPG2 and Syt1OPG2). How-
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Fig. 3 Sec61 and EMC knock-downs selectively inhibit TMP insertion. a Schematic of the modified in vitro assay used for analysis of total translation
products. Following translation, SP cells depleted of ER membrane components using siRNA were solubilised using Triton (TX-100). Total radiolabelled
products (i.e. membrane-associated and non-targeted nascent chains) were recovered by immunoprecipitation via the OPG2-tag and analysed by SDS-
PAGE and phosphorimaging. b Schematics of defined model substrates; the type II TMP asialoglycoprotein receptor 1 with an OPG2-tag (ASGR1OPG2) and
the TA protein cytochrome b5 with an OPG2-tag (Cytb5OPG2). c ASGR1OPG2 (top panel) and Cytb5OPG2 (bottom panel) synthesised in the presence
and absence of 1 µM Ipom-F using SP cells pre-treated with the indicated siRNA (NT, lanes 1–3; Sec61α-targeting, lanes 4–5; EMC2-targeting, lanes 6–7;
EMC5-targeting, lanes 8–9) were recovered and analysed as described in (a). d Relative membrane insertion efficiencies were calculated using the ratio of
N-glycosylated protein to non-glycosylated protein, relative to the NT control (set to 100% insertion efficiency). Quantifications are given as means ± SEM
for independent insertion experiments from separate siRNA treatments performed in triplicate (n= 3, biologically independent experiments). The
statistical significance of differences in the values for siRNA±Ipom-F translocation efficiency relative to the control (two-way ANOVA, DF and F values
shown in the figure) were determined using Tukey’s multiple comparisons test. e The effects of Ipom-F and Sec61α, EMC2 and EMC5 knock-downs on
ASGR1OPG2 and Cytb5OPG2 insertion are summarised together with biochemical properties of their transmembrane domains (TMDs). Estimated
hydrophobicity values (4Gapp)42 and the number of charged/polar amino acid residues (AAs) in the transmembrane domain were calculated as described
in the legend to Fig. 1. Statistical significance is given as n.s., non-significant P > 0.1; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Fig. 4 Type III TMPs utilise the EMC for membrane integration. a Representative structures of type III TMPs (all OPG2-tagged as indicated) together with
the biochemical properties of their transmembrane domains (TMDs). b Type III TMPs were synthesised using SP cells pre-treated with the indicated siRNA (NT,
lanes 1–3; Sec61α-targeting, lanes 4–5; EMC5-targeting, lanes 6–7), recovered and analysed as described in the legend to Fig. 4. c Quantification of type III TMP
insertion for HIV protein Vpu (OPG2Vpu), small cell adhesion glycoprotein containing an artificial N-glycan site (SMAGPOPG2), glycophorin C (GypCOPG2),
tumour necrosis factor receptor superfamily member 17 containing an artificial N-glycan site (BCMAOPG2), synaptotagmin 1 (Syt1OPG2) and a cytosolically
truncated version of Syt1OPG2 (Syt1-127-OPG2). Estimated hydrophobicity values (4Gapp)42 and the number of charged/polar amino acid residues (AAs) in the
transmembrane domain are as shown in Fig. 1. Statistical significance (two-way ANOVA, DF and F values shown in the figure) was determined as indicated in the
legend to Fig. 3. Statistical significance is given as n.s., non-significant P > 0.1; *P < 0.05; **P < 0.01; ****P < 0.0001.
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(~24%) reduction in the membrane insertion of GypCOPG2,
which we noted has the least hydrophobic transmembrane
domain of the type III TMPs analysed (Fig. 4; ΔGapp of −2.67
kcal/mol versus −3.32 to −4.10 kcal /mol)42.
The knock-down of EMC5 had a striking effect on the
membrane integration of four OPG2-tagged model type III
TMPs, with HIV-Vpu, GypC, SMAGP and Syt1 all showing
significantly lower levels of membrane integration (34–50%
reduced; Fig. 4b, c). Only the insertion of BCMA (Fig. 4b, c), a
type III TMP bearing an extremely hydrophobic transmembrane
domain (Fig. 4a; Supplementary Fig. 4), was unaffected. Thus, we
conclude that the majority of type III proteins require a
functional EMC for their efficient membrane insertion. Further-
more, and in contrast to most known EMC clients11,19–21, this
EMC-dependence does not appear to be strongly influenced by
the relative polarity of the transmembrane domains present in
our model type III TMPs (Fig. 4a, HIV-Vpu, GypC, SMAGP have
1, 3 and 5 hydrophilic residues respectively). However, by
comparing full-length Syt1, which has a longer than the average
cytosolic domain (Supplementary Fig. 4), with a C-terminally
truncated version more typical of our other model proteins (Syt1-
127-OPG2), we find evidence that the length of the cytosolic
domain may influence the EMC dependency of some type III
TMPs (Fig. 4, see “Discussion”).
Co-operation between Sec61 and the EMC for type III TMP
insertion. Having observed individual roles for both Sec61 and the
EMC during GypC integration (Fig. 4), we investigated the potential
interplay between these two complexes using co-depletion. Having
established that double siRNA-mediated knock-downs of Sec61α+
EMC2 and Sec61α+ EMC5 subunits were of comparable efficiency
to individual knock-downs (Fig. 5a, b versus Fig. 2c, d), we again
utilised OPG2-tagged ASGR1 and Cytb5 (Fig. 5c) as benchmark
TMPs. In accordance with its previously observed strong Sec61-
dependence (Fig. 3), the reduction in ASGR1 insertion following
double knock-down of both Sec61α+ EMC2 and Sec61α+ EMC5
was comparable to that achieved by Sec61α depletion alone. Inter-
estingly, the increase in ASGR1 insertion observed after EMC2
depletion was lost when Sec61α was co-depleted (Fig. 5c, d versus
Fig. 3c, d, see “Discussion”). Conversely, both double knock-downs
resulted in a reduction of Cytb5 insertion that was less pronounced
than that achieved by knocking down EMC5 alone and only mar-
ginally more effective than depleting Sec61α (Fig. 5c, d). We attribute
this behaviour to the ability of Cytb5 to utilise several alternate, and
apparently redundant, pathways for ER membrane insertion5,41. The
Ipom-F sensitivity of ASGR1 or Cytb5 was unaltered by the double
depletion of Sec61 and EMC subunits when compared to single
subunit depletions (Fig. 5c, d versus Fig. 3c, d).
In the case of type III TMP integration, we saw a strong
enhancement of the membrane insertion defect following double
depletion of Sec61α+ EMC5 for three model proteins, HIV-Vpu,
SMAGP and GypC (65 to 75% reduction; Fig. 5). When
compared to the effect of the individual knock-downs (Fig. 4
versus Fig. 5), this provides clear evidence for some element of
mechanistically important co-ordination or synergy between the
Sec61 complex and EMC during their membrane insertion. Even
for BCMA, which was unaffected by the individual depletion of
subunits from either complex, double subunit depletions now
resulted in a reduction of membrane insertion by 36% (Fig. 5c, d).
In short, for the majority of type III TMPs tested, efficient
membrane integration requires both the Sec61 complex and the
EMC, in line with previous reconstitution studies that have
implicated each complex in their membrane insertion4,19.
Paradoxically, a double depletion of Sec61α+ EMC5 reversed
the ~34% reduction in the membrane insertion of Syt1 seen
following EMC5 depletion alone (Figs. 4 and 5). However,
this effect was not seen with the truncated Syt1-127 variant
(Figs. 4 and 5), further indicating that the comparatively long
C-terminal region of Syt1 can influence its membrane insertion
(see “Discussion”).
SRP receptor promotes insertion of type III TMPs. To probe
how the Sec61 complex and the EMC may co-operate during the
integration of bona fide type III TMPs, we next investigated the
role of the SRP receptor complex that is predicted to act
upstream of these two membrane insertase complexes (Fig. 6a).
To this end, we first analysed the levels of the SRP receptor α-
subunit (SRα) in SP cells depleted of Sec61 and/or EMC sub-
units. We found SRα expression was upregulated following
Sec61α depletion (Sec61α-kd, Sec61α+ EMC2-kd, Sec61α+
EMC5-kd), as previously reported26, but was either unaffected
(EMC2-kd) or moderately reduced (EMC5-kd) by EMC subunit
depletion alone (Supplementary Fig. 5). Furthermore, SP cell
membrane-associated levels of SRP54, the SRP subunit that
engages SRα43, were not significantly altered by any knock-down
condition used in this study (Supplementary Fig. 5). Hence,
initial access to the Sec61 complex via the SRP-dependent co-
translational pathway is most likely either unperturbed or
enhanced at the level of SRP-mediated membrane targeting and
SRP receptor binding following such knock-downs.
Having established that we could efficiently deplete SRα by
siRNA-mediated knock-down, both alone and in combination
with Sec61α or EMC5 subunits (~70– 90%; Fig. 6b, c), we
investigated the effects of such depletions on membrane insertion.
For the type II TMP, ASGR1, knock-down of SRα alone had a
minor though non-significant effect on membrane integration
(SRα-kd= 34% reduction versus Sec61α-kd= 62% reduction; see
“Discussion”), whilst co-depletions of SRα did not enhance the
effect of knocking down Sec61α or EMC5 alone (Fig. 6d, e).
Likewise, for the TA protein, Cytb5, co-depletion of SRα did not
enhance the already strong membrane insertion defect observed
upon EMC5 knock-down, although we did observe an enhanced
defect in Cytb5 insertion when SRα and Sec61α knock-downs
were combined (Fig. 6d, e).
Type III TMPs that showed the strongest defects in membrane
insertion following combined knock-down of EMC5+ Sec61α
(Vpu and GypC; see Figs. 5f and 6e) also showed significantly
reduced levels of membrane insertion following SRα depletion
alone (Fig. 6e). When SRα depletion was combined with that of
either EMC5 or Sec61α, an even stronger defect in the membrane
insertion of Vpu and GypC was observed, comparable to the
reduction achieved following co-depletion of EMC5 and Sec61α
(Fig. 6e). This behaviour is consistent with a model for type III
TMP insertion where the SRP receptor, EMC and Sec61 complex
all participate in a single co-translational pathway (Fig. 7).
Comparable, though less pronounced, defects in the membrane
insertion of BCMA and Syt1-127 were also seen after combined
depletions (EMC5+ Sec61α-kd, SRα+ EMC5-kd and SRα+
Sec61α-kd; see Fig. 6e), further supporting the proposal that
these three components act on the same pathway. Likewise, for
Syt1, where co-depletion of EMC5 and Sec61α reversed the
insertion defect seen upon EMC5 knock-down alone (cf. Figs. 4
and 5), co-depletion of SRα with either EMC5 or Sec61α resulted
in an enhanced insertion defect. Only in the case of SMAGP and
Syt1-127 did a knock-down of EMC5 and Sec61α appear more
effective than either of the SRα combinations tested (Fig. 6e). In
summary, these data strongly suggest that the model type III
TMPs investigated in this study are targeted to their site of ER
membrane integration via the SRP-dependent pathway, although
this ER delivery route may be non-exclusive (see “Discussion”).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02363-z ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:828 | https://doi.org/10.1038/s42003-021-02363-z | www.nature.com/commsbio 7
Discussion
Although previously implicated in the biogenesis of specific TA
proteins and subdomains of multi-pass TMPs14,16–19, the
importance of EMC-mediated membrane insertion for the bio-
genesis of most single-pass TMPs remains under-explored.
Prompted by the ability of several naturally occurring type III
TMPs (four mammalian and one viral) to completely bypass the
effects of Sec61 inhibitors (Fig. 1 and Supplementary Fig. 1)1, we
have used Ipom-F (Figs. 1, 3–5) and selective siRNA-mediated
knock-downs of Sec61, EMC and SRP receptor complex subunits,
both alone and in combination (Figs. 2–6), to explore the bio-
genesis of type III TMPs and provide a unifying model for their
ER insertion (Fig. 7).
Amongst our panel of type III TMPs, only GypC showed a
significant reduction in membrane integration following Sec61α
depletion (∼25%, Fig. 4). Thus, loss of Sec61 function alone, either
through knock-down or Ipom-F inhibition, has little or no effect on
the type III TMPs tested. A much clearer disruption is seen fol-
lowing EMC5 knock-down, with four type III TMPs showing
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thereby confirming that the EMC plays an important role in the
biogenesis of bona fide type III TMPs19. However, when knock-
downs of Sec61α and EMC5 are combined, we see clear evidence
that both complexes are necessary for efficient type III TMP
insertion (Fig. 5). Furthermore, type III TMPs which show the
biggest reductions in membrane insertion following EMC5 deple-
tion alone (HIV-Vpu, SMAGP and GypC; Fig. 4) all showed clearly
enhanced defects following a double knock-down with Sec61α (∼65
to ∼75% reduction; Fig. 5). We therefore conclude that the bio-
genesis of type III TMPs normally involves both the EMC and the
Sec61 complex (cf. Fig. 7).
The co-translational insertion of nascent membrane proteins
via the Sec61 complex is typically dependent upon their SRP-
mediated delivery (cf. Fig. 6a), and we therefore tested the
hypothesis that the SRP receptor acts prior to the EMC/Sec61-
dependent membrane insertion of type III TMPs. With the
exception of the viral Vpu protein, the depletion of SRα alone had
a comparatively modest effect on all three classes of TMP ana-
lysed (Fig. 6e). Although we cannot exclude that the residual SRα
remaining after depletion (~30%) can service multiple ER
membrane insertion sites, this seems unlikely given SRP receptor
levels are rate limiting for SRP-dependent targeting44. Hence, we
speculate that the comparatively modest defects seen following
SRα depletion alone reflect the ability of nascent TMPs to exploit
alternative mechanisms for ER delivery, such as the putative
mammalian SND pathway5,41,45,46. For type III TMPs, the impact
of SRα depletion is clearer when combined with the knockdown
of EMC5 or Sec61α. In each case, the co-depletion of SRα+
EMC5, SRα+ Sec61α or EMC5+ Sec61α all result in strong and
comparable defects in membrane insertion (cf. Fig. 6e), leading us
to conclude that the SRP receptor, EMC and Sec61 can all act in
concert during type III TMP insertion (Fig. 7).
On the basis of these findings, we propose that, following SRP-
mediated delivery to the ER localised SRP receptor43 (Fig. 7a), the
EMC and Sec61 complex are co-ordinated to provide an alter-
native pathway for the N-terminal translocation and membrane
insertion of type III TMPs. Given the consistent insensitivity of
type III TMPs to inhibition by Ipom-F (Figs. 1 and 3–5), it is
extremely unlikely that this route involves membrane access via
the Sec61 lateral gate, which would probably be occluded by
bound Ipom-F1 (Fig. 7b, route 1), as recently established for
mycolactone47. Thus, rather than directly facilitating the inte-
gration of type III TMPs, we propose that the Sec61 complex acts
to complement the membrane insertase activity of the EMC
(Fig. 7b, route 2). In practice, such a translocation independent
role for the Sec61 complex may involve its co-ordination of SRP-
dependent delivery48 and/or binding to the ribosome-nascent
chain complex31. Intriguingly, we find preliminary evidence that
the EMC may also influence co-translational insertion via the
Sec61 complex. Hence, depletion of EMC2, but not EMC5,
selectively enhanced ASGR1 insertion by ∼90% via a pathway
that remained Ipom-F sensitive (Fig. 3). This increase was not
sustained following co-depletion of Sec61α and EMC2 (Fig. 5),
further suggesting some interplay between Sec61 and the EMC
(Fig. 7b, route 2) and supporting the proposal that the functions
of the EMC extend beyond those of a simple membrane
insertase13.
Recent structural studies identified a conserved vestibule
formed by EMC3/EMC6 as the site of EMC-mediated trans-
membrane domain insertion into the ER11–14. EMC3 is structu-
rally homologous with YidC13, an insertase that acts downstream
of SRP in bacteria and facilitates membrane insertion, either
alone or together with SecY (a Sec61α orthologue)49–52. Transient
contact is observed between SecY and flexible cytosolic domains
of YidC during the membrane insertion of substrates50 and it was
recently suggested that a YidC-SecYEG complex enables the
insertion of certain bacterial membrane proteins52. By analogy,
and whether transiently or via the formation of an as yet uni-
dentified EMC-Sec61 complex, it seems feasible that the equiva-
lent methionine-rich C1 loop and/or C-terminus of EMC3 may
encounter Sec61α during the selective capture of type III TMP
clients and direct their transmembrane domains to the EMC
insertase site13 (cf. Fig. 7b, route 2). In addition, as for YidC51,53,
positively charged regions within the cytosolic domains of one or
more EMC subunits may promote binding to the ribosome-
nascent chain complex (Fig. 7b, routes 2 and 3). Given that a
stable or prolonged interaction between the EMC and a
ribosome-engaged Sec61 complex operating on the normal co-
translational pathway appears unlikely12, the capacity of the EMC
to support type III TMP insertion in isolation (Fig. 7b, route 3) is
supported by the minimal defect observed following knock-down
of Sec61α alone (Fig. 4).
The type III TMPs studied here are fairly typical of the wider
group (Supplementary Fig. 4) and, on that basis, we propose that
most type III TMPs (38 in humans, see Supplementary Data 1)
follow our proposed biosynthetic pathway (Fig. 7). In contrast to
previous studies of other clients, we find no evidence that
transmembrane domains of enriched polarity20,21 confer EMC-
dependence to single-pass type III TMPs (Fig. 4, Fig. 6, Sup-
plementary Fig. 4). Likewise, the transmembrane domains of the
type III TMPs studied here (ΔGapp of −2.67 to −4.10 kcal/mol;
see Fig. 4), and the properties of type III SARS-CoV-2 envelope
protein54, indicate that low to moderate transmembrane domain
hydrophobicity is also not a pre-requisite for EMC-dependent
membrane insertion15. In the case of bona fide type III TMPs,
we propose that it is the necessity to translocate their pre-
formed hydrophilic N-terminus in concert with the integration
of their single transmembrane domain12 that dictates their
entry into the EMC/Sec61-mediated membrane insertion path-
way (Fig. 7).
Fig. 5 Depletion of Sec61 and EMC further inhibits type III TMP insertion. a The effects of transfecting HeLa cells with non-targeting (NT; lane 1), Sec61α
+EMC2-targeting (lane 2) and Sec61α+EMC5-targeting (lane 3) siRNAs were determined after semi-permeabilisation by immunoblotting for Sec61α,
EMC2, EMC5 and EMC6 subunits, OST48 and LMNB1. b The efficiencies of siRNA-mediated knock-down (bold) were calculated as a proportion of the
signal intensity obtained with the NT control (set as 100%). c ASGR1OPG2 (left panel) and Cytb5OPG2 (right panel) synthesised in the presence and
absence of 1 µM Ipom-F using SP cells pre-treated with the indicated siRNA (NT, lanes 1–3; Sec61α+ EMC2-targeting, lanes 4–5; Sec61α+ EMC5-
targeting, lanes 6–7) were recovered and analysed as described in the legend to Fig. 3. d The relative membrane insertion efficiencies for ASGR1OPG2 and
Cytb5OPG2 in SP cells depleted of Sec61α+ EMC2 or Sec61α+ EMC5 subunits (double knock-downs) were calculated using the ratio of N-glycosylated
protein to non-glycosylated protein, relative to the NT control (set to 100% insertion efficiency). e Type III proteins (OPG2-tagged) as detailed in the
legend to Fig. 4 were synthesised in the presence and absence of 1 µM Ipom-F using SP cells pre-treated with the indicated siRNA (NT, lane 1; Sec61α+
EMC5-targeting, lanes 2–3), recovered, analysed and (f) their relative membrane-insertion efficiencies quantified as described in parts (c) and (d). All
quantifications are given as means ± SEM for three separate siRNA treatments (n= 3 biologically independent experiments). Statistical significance (two-
way ANOVA, DF and F values shown in the figure) was determined using Tukey’s multiple comparisons test and is given as n.s., non-significant >0.1; **P <
0.01; ***P < 0.001; ****P < 0.0001.
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Our findings with BCMA and Syt1 indicate that individual
variations in transmembrane domain hydrophobicity and cyto-
solic domain length may affect the efficiency of type III TMP
insertion by this alternate EMC/Sec61-mediated route, perhaps
by influencing transmembrane domain capture by and/or mem-
brane insertion at the EMC16,19. In the case of BCMA (ΔGapp of
−4.10 kcal/mol), co-depletion experiments suggest at least some
nascent chains follow the pathway depicted in Fig. 7. However, it
also appears that BCMA can either utilise the residual SRP
receptor/EMC/Sec61 machinery particularly effectively and/or
exploit alternative, partially redundant, routes for its ER mem-
brane insertion5,18,41. Type III TMPs with longer than average
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Fig. 6 Type III TMP insertion is dependent on the SRP receptor. a A model of SRP-dependent targeting to the ER membrane: the SRP ‘scans’ the emerging
nascent chain of a translating ribosome for hydrophobic ER signal-sequences or transmembrane domains, binds the ribosome-nascent chain complex and
delivers it to the ER membrane via its interaction with the SRP receptor, prior to membrane insertion43. The SRP receptor is a heterodimer comprised of the
ER membrane-integrated beta subunit (SRβ) anchoring the peripherally associated cytosolic alpha subunit (SRα). b The effect of transfecting HeLa cells
with non-targeting (NT; lane 1), SRα-targeting (lane 2), SRα+ EMC5-targeting (lane 3) and SRα+ Sec61α-targeting (lane 4) siRNAs was determined after
semi-permeabilisation by quantitatively immunoblotting for: SRα, Sec61α, EMC2, EMC5, EMC6, OST48 and LMNB1. c The efficiency and statistical
significance of siRNA-mediated single and double SRα knock-downs were calculated as a proportion of the signal intensity obtained with the NT control
(set as 100%), and using LMNB1 as a loading control, as before (see Fig. 2). Other components tested were unaffected (see Supplementary Fig. 5).
d OPG2-tagged control (first and second panels) and type III TMPs synthesised using SP cells pre-treated with the indicated siRNAs (NT, lane 1; SRα lane
2, SRα+ EMC5, lane 3; SRα+ Sec61α-targeting, lane 4) were recovered and analysed as described in the legend to Fig. 3. e Relative membrane insertion
efficiencies were calculated using the ratio of N-glycosylated protein to non-glycosylated protein, relative to the NT control (set to 100% insertion
efficiency). To permit visual comparison across knock-down conditions, data are shown side by side with the membrane insertion efficiency achieved in SP
cells depleted of either Sec61α and EMC5 subunits alone and in combination (these data are respectively from Figs. 3–5). Quantifications are given as
means ± SEM for three separate siRNA treatments (n= 3, biologically independent experiments) and statistical significance (RM one-way ANOVA, DF and
F values shown in the figure) was determined using Dunnett’s multiple comparisons test (versus two-way ANOVA in Figs. 3–5). Statistical significance is
given as n.s., non-significant P > 0.1; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. N.B. When the data are re-analysed in this way, the effect of a single
knock-down of Sec61α on the membrane insertion of Cytb5 is now deemed statistically significant (cf. Fig. 3).
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Fig. 7 A model for type III TMP biogenesis. a Type III TMPs are first delivered to the ER membrane via the SRP-dependent co-translational pathway (as in
Fig. 6). b Following engagement of SRP-SRα, we propose that the Sec61 complex may act as a ribosome docking site but, as opposed to the insertion of
type I/II TMPs which proceeds via the lateral gate (route 1), Sec61 does not fully engage the transmembrane domain. Instead, the type III transmembrane
domain is captured by the EMC and inserted into the membrane, most likely via the EMC3/EMC6 insertase site (route 2; pink and cyan coloured
membrane-spanning subunits respectively); an action assisted by local thinning of the membrane13. This mechanism is not impacted by the binding of
Ipom-F which, by analogy to mycoclactone47, impedes access to the Sec61 lateral gate. Alternatively, the Sec61 complex may support EMC-dependent
translocation by facilitating the release of the SRP from the RNC-SRP-SR complex36, thereby permitting type III transmembrane domain capture by the
EMC without ribosomal engagement of the Sec61 complex. Whilst the relative orientations of Sec61, the EMC and the ribosome-nascent chain complex are
as yet unknown, such a mechanism would be consistent with the recent suggestion that steric limitations (see red arrow head) between a Sec61-engaged
ribosome and the cytosolic domain of the EMC restrict the proximity of the Sec61 lateral gate and the EMC insertase site to ~110Å12 (cf. double headed pink
arrow). Alternatively, and/or additionally, the EMC may bind directly to ribosomes and insert type III transmembrane domains independently of the Sec61
complex, in a manner analogous to that of YidC (route 3). EMC schematics for route 2 and 3 are shown rotated 180° around the vertical axis in order to
show potentially relevant EMC subunit locations. Potential sites of client transmembrane domain capture by the EMC are indicated, these may include: (i) a
flexible region of the EMC3/EMC6 insertase site (routes 2–3, white asterisk) and/or (ii) a hydrophobic cleft at the interface between EMC2-EMC8/9
(route 3, black asterisk).
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cytoplasmic domains (average and median length of 330 and 261
amino acids respectively; see Supplementary Fig. 4 and Supple-
mentary Data 1), as exemplified by Syt1, appear resistant to co-
depletion of EMC/Sec61 subunits, but do show a defect when
either component is co-depleted with SRα (Figs. 5f, 6e). We
speculate that the synthesis of the extra ∼300 residues present in
full-length Syt1 increases the residence time of its nascent chain
on the ER membrane, thereby enhancing its ability to engage the
residual components remaining after knockdown, and/or utilise
alternative factors. In summary, we have identified key compo-
nents that mediate type III TMP biogenesis and propose a uni-
fying model whereby, following SRP-mediated delivery to the ER,
these proteins are integrated into the membrane by the EMC
acting in concert with the Sec61 complex (Fig. 7).
Methods
Ipom-F and antibodies. Ipom-F was synthesised as previously described55–57. The
goat polyclonal anti-LMNB1 antibody, which served as a loading control for the
amount of SP cells present per translation reaction, was purchased from Santa Cruz
(clone M-20, sc-6217). Rabbit polyclonal antibodies against EMC5 and EMC6 were
purchased from Bethyl Laboratories (A305-832-A) and Abcam (ab84902) respec-
tively. The mouse monoclonal antibody against EMC2 was purchased from Santa
Cruz (sc-166011). The mouse monoclonal antibody recognising the OPG2-tag22,
rabbit polyclonal anti-OST4828 and guinea pig anti-CAML5 were as described
previously. Rabbit antisera against Sec61α (C-terminus) and hSnd2 were gifts from
Sven Lang (University of Saarland, Homburg, Germany) and rabbit antisera against
SRα were provided by Martin Pool (University of Manchester),.
Constructs. All cDNAs encode human genes unless specified otherwise. The
cDNAs for BCMA (Uniprot: Q02223) and SMAGP (Uniprot: Q0VAQ4) were
purchased from Sino Biological (HG10620-UT and HG25714-UT). The cDNA for
the human immunodeficiency virus type I group M subtype B (isolate BRU/LAI)
protein HIV-Vpu (Uniprot: P05923) was custom synthesised to order
(GenScript)58. ASGR159, CD3δ1, Cytb5OPG222, GypC4, Ii60, bovine PPL23, yeast
ppαF22, Sec61βOPG222, rat Syt11, VCAM11 were as previously described. Artificial
N-glycosylation sites (SMAGP-L4N, BCMA-Y13T) and OPG2-tagged substrates
(ASGR1OPG2, SMAGP-L4N-OPG2, GypCOPG2, BCMA-Y13T-OPG2,
Syt1OPG2, OPG2Vpu) were generated by site-directed mutagenesis (Stratagene
QuikChange, Agilent Technologies) using the relevant forward and reverse primers
(Integrated DNA Technologies). Linear DNA templates were generated by PCR
and mRNA transcribed using T7 or SP6 polymerase. All primer combinations for
mutagenesis and PCR are listed in Tables 1 and 2 respectively.
Knock-down and preparation of SP cells. HeLa cells (human epithelial cervix
carcinoma cells, mycoplasma-free), as previously described61, were provided by
Martin Lowe (University of Manchester) and were cultured in DMEM supple-
mented with 10% (v/v) FBS and maintained in a 5% CO2 humidified incubator at
37 °C. Knock-down of target genes were performed similarly to previously
described methods18,26,33. Briefly, 1 × 106 cells were seeded per 10 cm2 dish and, 24
h after plating, cells were transfected with either control siRNA (ON-TARGETplus
Non-targeting control pool; Dharmacon), SEC61A1 siRNA (Sec61α-kd, GE
Healthcare, sequence AACACUGAAAUGUCUACGUUUUU), TTC35 siRNA
(EMC2-kd, Santa Cruz, sc-77588), MMGT1 siRNA (EMC5-kd, ThermoFisher
Scientific, s41129) or SRPRA siRNA (SRα-kd, GE Healthcare, sequence GAG-
CUUGAGUCGUGAAGACUU) at a final concentration of 20 nM using INTER-
FERin (Polyplus, 409-10) as described by the manufacturer. For SEC61A1 silencing,
either alone or in combination with MMGT1 silencing (Sec61α+ EMC5-kd), the
medium of the non-targeting control and targeted knock-downs was changed 24 h
post-transfection and cells were re-transfected with siRNA a second time26. 96 h
post-initial transfection, cells were SP using a modification of the previously
described method28. Briefly, cells were detached by incubation with 3 mL of 0.25%
trypsin-EDTA solution (Sigma-Aldrich) for 10 min at RT, mixed with 4 mL of
KHM buffer (110 mM KOAc, 2 mM Mg(OAc)2, 20 mM HEPES-KOH pH 7.2)
supplemented with 100 µg/mL Soybean trypsin inhibitor (Sigma-Aldrich, T6522)
and centrifuged at 250 g for 3 min at 4 °C. The pellet was resuspended in 4 mL
KHM buffer supplemented with 80 µg/mL high purity digitonin (Calbiochem) and
cells incubated on ice to selectively permeabilise the plasma membrane. After 10
min, cells were again centrifuged at 250 × g for 3 min before resuspension in
HEPES buffer (90 mM HEPES, 50 mM KOAc, pH 7.2) and incubation on ice for
10 min. Cells were pelleted by centrifugation once more, resuspended in 100 µL
KHM buffer and endogenous mRNA removed by treatment with 0.2 U Nuclease S7
Micrococcal nuclease, from Staphylococcus aureus (Sigma-Aldrich, 10107921001)
and 1 mM CaCl2 at RT for 12 min before quenching by the addition of EGTA to 4
mM final concentration. Cells were centrifuged at 13,000 × g for 1 min and
resuspended in an appropriate volume of KHM buffer to give a suspension of 3 ×
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cells were included in translation master mixes such that each translation reaction
contained 2 × 105 cells/mL.
In vitro synthesis and membrane insertion: analysis of membrane-associated
products. Translation and membrane insertion/translocation assays (20 μL) were
performed in nuclease-treated rabbit reticulocyte lysate (Promega) in the presence
of EasyTag EXPRESS 35S Protein Labelling Mix containing [35S] methionine
(Perkin Elmer) (0.533 MBq; 30.15 TBq/mmol), 25 μM amino acids minus
methionine (Promega), 1 μM Ipom-F, or an equivalent volume of DMSO, 6.5%
(v/v) ER-derived membranes and ~10% (v/v) of in vitro transcribed mRNA
encoding the relevant precursor protein1,62. Translation reactions using nuclease-
treated canine pancreatic microsomes (from stock with OD280= 44/mL) were
performed for 20 min at 30 °C whereas those using SP HeLa cells were performed
on a 1.5X scale for 1 h at 30 °C25,28. Following incubation with 0.1 mM puromycin
for 10 min at 30 °C to ensure translation termination and ribosome release of newly
synthesised proteins, microsomal or SP cell membrane-associated fractions were
recovered by centrifugation through an 80 μL high-salt cushion (0.75 M sucrose,
0.5 M KOAc, 5 mM Mg(OAc)2, 50 mM Hepes-KOH, pH 7.9) at 100,000 × g for
10 min at 4 °C and the pellet suspended directly in SDS sample buffer (Fig. 1 and
Supplementary Fig. 1).
In vitro synthesis and membrane insertion: analysis of total translation pro-
ducts. In order to define the effects of Sec61α, EMC2 or EMC5 knock-down on the
in vitro ER insertion of membrane proteins, we modified our SP cell procedure to
recover all translation products (i.e. membrane-associated and non-targeted nas-
cent chains) via immunoprecipitation (Fig. 3a). This enabled us to compare the
efficiency of N-glycosylation as a proportion of the total protein synthesised in each
condition, thereby ruling out any effect resulting from differences in translation or
minor variations in the amount of SP cells present. The addition of the OPG2-tag
does not affect TMP sensitivity to Ipom-F and recovery via immunoprecipitation
was consistently robust (Supplementary Fig. 3). Furthermore, inclusion of the
OPG2-tag (two N-linked glycan sites) at the C-terminus of our type III TMPs
(typically one N-linked glycan site) allowed us to confirm that none of these model
substrates are inserted with the wrong topology (NCyt/CLum) under any knock-
down condition, as has previously been observed with some precursors following
destabilisation of the EMC18. On this basis, we performed translation reactions
using siRNA-treated SP cells and OPG2-tagged TMP mRNA as described in the
previous section. Following puromycin treatment, the total reaction material was
then diluted with nine volumes of Triton immunoprecipitation buffer (10 mM
Tris-HCl, 140 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, pH 7.5), supple-
mented with 5 mM PMSF and 1mM methionine, and samples were incubated
under constant agitation with appropriate antisera (1:200 dilution) for 16 h at 4 °C
to recover both the membrane-associated and non-targeted nascent chains. Sam-
ples were then incubated under constant agitation with 10% (v/v) Protein-A-
Sepharose beads (Genscript) for a further 2 h at 4 °C before recovery by
centrifugation at 13,000 × g for 1 min. Protein-A-Sepharose beads were washed
with Triton immunoprecipitation buffer prior to suspension in SDS sample buffer.
SDS-PAGE and immunoblotting. All samples were suspended in SDS sample
buffer, treated with 1000 U of Endoglycosidase Hf or Endo H (respectively, for
molecular weight proteins ~10-50 kDa or ~50–100 kDa; New England Biolabs,
P0703S or P0702S) where indicated, and denatured for 1 h at 37 °C prior to
resolution by SDS-PAGE (16% PAGE, 120 V, 120 min). To analyse the translation
products, gels were fixed for 5 min (20% (v/v) MeOH, 10% (v/v) AcOH), dried for
2 h at 65 °C and the radiolabelled species visualised using a Typhoon FLA-700
(GE Healthcare) following exposure to a phosphorimaging plate for 24–72 h.
Knock-down efficiencies (EMC2, EMC5, Sec61α, SRα) and controls (EMC6, OST,
LMNB1, hSnd2, CAML) were determined by quantitative immunoblotting. Fol-
lowing transfer to a PVDF membrane in transfer buffer (0.06 M Tris, 0.60M
glycine, 20% MeOH) at 300 mA for 2.5 h, PVDF membranes were incubated in 1X
Casein blocking buffer (10X stock from Sigma-Aldrich, B6429) made up in TBS,
incubated with appropriate primary antibodies (1:500 or 1:1000 dilution) and
processed for fluorescence-based detection as described by LI-COR Biosciences
using appropriate secondary antibodies (IRDye 680RD Donkey anti-Goat, IRDye
680RD Donkey anti-Rabbit, IRDye 800CW Donkey anti-Guinea pig, IRDye
800CW Donkey anti-Mouse) at 1:10,000 dilution. Signals were visualised using an
Odyssey CLx Imaging System (LI-COR Biosciences).
Statistics and reproducibility. Bar graphs depict either the efficiencies of siRNA-
mediated knock-down in SP cells calculated as a proportion of the protein content
when compared to the NT control or membrane insertion efficiencies calculated as
the ratio of N-glycosylated protein to the amount of non-glycosylated protein, with all
control samples set to 100%. Replicates, whether in vitro membrane insertion assays
or immunoblot analyses of siRNA target genes, were performed using individual
siRNA-mediated knock-downs (n= 3, biologically independent experiments).
Replicates of immunoblot analyses examining the effects of siRNA-mediated knock-
downs on other, non-targeted ER membrane proteins were performed using indivi-
dual siRNA-mediated knock-downs (n= 2 or n= 3, biologically independent
experiments) as indicated (see Supplementary Fig. 5). Normalised values were used
for statistical comparison (RM one-way or two-way ANOVA; DF and F values are
shown in each figure as appropriate and the multiple comparisons test used are
indicated in the figure legend). Statistical significance is given as n.s., non-significant
P > 0.1; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and supplementary information files. Uncropped and unedited blot/gel images
Table 2 Primer list 2.
Recombinant cDNA Vector Species Forward primer (5′-3′) Reverse primer (5’-3’) RNA Polymerase
ASGR159 SP64 Human CCAGAAACTCAGAAGGGTCG CAGGAAACAGCTATGAC SP6
ASGR1-OPG2 SP64
BCMA-Y13T pCMV3 Human CGCAAATGGGCGGTAGGCGTG TAGAAGGCACAGTCGAGG T7
BCMA Y13T-OPG2 pCMV3
CD3δ1 pcDNA3 Human CGCAAATGGGCGGTAGGCGTG TCACATCATCATCTTGTTCC
GAGCCCAGTTTCC
T7
Cytb5OPG2 pcDNA3 Human CGCAAATGGGCGGTAGGCGTG TAGAAGGCACAGTCGAGG T7
GypC4 pGEM4 Human GTGGATAACCGTATTACCGCC CTCTGACGGCAGTTTACGAG T7
GypC-OPG2 pGEM4
Ii60 pGEM3 Human CTCTGACGGCAGTTTACGAG GTGGATAACCGTATTACCGCC SP6
OPG2Vpu58 pTNT HIV GGGAAACGCCTGGTATCT CTCAAGACCCGTTTAGAG T7
PPL23 pGEM4 Bovine GTGGATAACCGTATTACCGCC CTCTGACGGCAGTTTACGAG T7
ppαF22 SP65 Yeast CCAGAAACTCAGAAGGGTCG CAGGAAACAGCTATGAC SP6
Sec61βOPG222 pcDNA5 Human CGCAAATGGGCGGTAGGCGTG TAGAAGGCACAGTCGAGG T7
SMAGP-L4N pCMV3 Human CGCAAATGGGCGGTAGGCGTG TAGAAGGCACAGTCGAGG T7
SMAGP-L4N-OPG2 pCMV3





VCAM11 pcDNA3 Human CGCAAATGGGCGGTAGGCGTG TAGAAGGCACAGTCGAGG T7
A list of primer sequences that were used for PCR amplification to generate linear DNA templates suitable for transcription.
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are included in Supplementary Fig. 6. Analysis of the characteristics of Uniprot
annotated type III TMPs are presented in Supplementary Data 1. All numerical data and
statistical analyses are available in Supplementary Data 2.
Received: 18 November 2020; Accepted: 17 June 2021;
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